Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

As the science stands, the vast majority of the roughly eight million people in South Africa living with HIV will have to get ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

CRISPR Therapeutics Forward-Looking Statement Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of ...

To separate AI hype from reality in medicine, a doctor and author of a book on generative AI’s future in medicine suggests asking three simple questions.

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

In June, Intellia's Phase I study of NTLA-2002 reported that all patients dosed with the drug had responded, with a mean 98% ...